Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Lufax Holding Ltd (LU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Lufax Holding Ltd — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $111.11 (market cap $12.58B), while Lufax Holding Ltd trades at $1 (market cap $982.89M). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 12.8× Lufax Holding Ltd's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Lufax Holding Ltd for 13 Days on average.
| HALO | LU | |
|---|---|---|
Market Cap | $12.58B | $982.89M |
Volume | 2,179,278 | 3,323,384 |
Sector | Health | Financials |
52-Week High | $115.22 | $3.93 |
52-Week Low | $61.63 | $0.95 |
Typical Hold Time | 0 Days | 13 Days |
Enterprise Value | $14.49B | $58.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Lufax (LU) trades at $0.98, showing minimal daily movement with a 0.09% gain. The stock faces significant fundamental challenges with consecutive quarterly losses and declining revenue, though valuation metrics appear deeply discounted with P/S of 0.25 and P/B of 0.07. Recent corporate actions include a 10:1 reverse stock split effective October 2026. Technical indicators show mixed signals with bearish moving averages but bullish oscillators, while analyst sentiment remains predominantly positive despite operational headwinds.
LU presents a high-risk, event-driven opportunity with deep value characteristics but substantial operational challenges. The company's negative profit margins and declining revenue trajectory create significant execution risk, though strong backing from parent company Ping An and potential Hong Kong listing catalysts offer upside potential. Investors should weigh the discounted valuation against persistent profitability concerns and regulatory pressures in China's financial services sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
